Torrent Pharmaceuticals Limited (BOM:500420)
India · Delayed Price · Currency is INR 4,482.00
-128.15 (-2.78%)
At close: Oct 23, 2026
Torrent Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 174,417 | 139,797 | 115,161 | 107,278 | 96,202 | 85,080 | |
Revenue Growth | 42.40% | 21.39% | 7.35% | 11.51% | 13.07% | 6.29% |
Cost of Revenue | 42,012 | 33,882 | 27,759 | 26,862 | 27,352 | 24,420 |
Gross Profit | 132,406 | 105,916 | 87,402 | 80,416 | 68,850 | 60,660 |
Selling, General & Admin | 32,873 | 27,313 | 22,708 | 20,166 | 17,052 | 15,483 |
Other Operating Expenses | 41,378 | 33,018 | 27,484 | 26,573 | 23,377 | 20,865 |
Operating Expenses | 93,408 | 71,518 | 58,141 | 54,693 | 47,449 | 42,967 |
Operating Income | 38,998 | 34,398 | 29,261 | 25,724 | 21,400 | 17,693 |
Interest Expense | -8,857 | -3,847 | -2,514 | -3,526 | -3,322 | -2,529 |
Interest & Investment Income | 384.3 | 384.3 | 201.9 | 114.8 | 147.8 | 71.5 |
Currency Exchange Gain (Loss) | -1,834 | -1,834 | -166.1 | -39.1 | -180.8 | 1,695 |
Other Non Operating Income (Expenses) | 24.4 | 24.4 | 6.9 | 314.4 | 61.1 | 76 |
EBT Excluding Unusual Items | 28,715 | 29,125 | 26,790 | 22,587 | 18,106 | 17,007 |
Merger & Restructuring Charges | - | - | - | - | - | -4,847 |
Gain (Loss) on Sale of Investments | 309.4 | 309.4 | 167.3 | 179.9 | 195.1 | 101.4 |
Gain (Loss) on Sale of Assets | 176.6 | 176.6 | 13.4 | -0.2 | 216.2 | - |
Asset Writedown | -1.7 | -1.7 | - | -129.7 | -45.6 | -2.3 |
Other Unusual Items | -1,068 | -887.5 | -242.1 | 883.8 | - | - |
Pretax Income | 28,132 | 28,722 | 26,728 | 23,521 | 18,472 | 12,259 |
Income Tax Expense | 7,140 | 7,340 | 7,616 | 6,957 | 6,019 | 4,487 |
Earnings From Continuing Operations | 20,992 | 21,382 | 19,113 | 16,564 | 12,452 | 7,772 |
Minority Interest in Earnings | 251.9 | 251.9 | - | - | - | - |
Net Income | 21,244 | 21,634 | 19,113 | 16,564 | 12,452 | 7,772 |
Net Income to Common | 21,244 | 21,634 | 19,113 | 16,564 | 12,452 | 7,772 |
Net Income Growth | -0.74% | 13.19% | 15.39% | 33.02% | 60.22% | -37.92% |
Shares Outstanding (Basic) | 359 | 338 | 338 | 338 | 338 | 338 |
Shares Outstanding (Diluted) | 359 | 338 | 338 | 338 | 338 | 338 |
Shares Change | 6.17% | - | - | - | - | - |
EPS (Basic) | 59.12 | 63.92 | 56.47 | 48.94 | 36.79 | 22.96 |
EPS (Diluted) | 59.12 | 63.92 | 56.47 | 48.94 | 36.79 | 22.96 |
EPS Growth | -6.51% | 13.19% | 15.39% | 33.02% | 60.22% | -37.92% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 35,663 | 23,453 | 19,732 | 28,333 | 17,942 | 16,004 |
Free Cash Flow Per Share | 99.25 | 69.30 | 58.30 | 83.72 | 53.01 | 47.29 |
Dividend Per Share | - | 38.000 | 32.000 | 28.000 | 22.000 | 16.500 |
Dividend Growth | - | 18.75% | 14.29% | 27.27% | 33.33% | -5.71% |
Gross Margin | 75.91% | 75.76% | 75.89% | 74.96% | 71.57% | 71.30% |
Operating Margin | 22.36% | 24.61% | 25.41% | 23.98% | 22.25% | 20.80% |
Profit Margin | 12.18% | 15.47% | 16.60% | 15.44% | 12.94% | 9.13% |
Free Cash Flow Margin | 20.45% | 16.78% | 17.14% | 26.41% | 18.65% | 18.81% |
EBITDA | 57,538 | 44,968 | 36,758 | 33,249 | 28,026 | 23,823 |
EBITDA Margin | 32.99% | 32.17% | 31.92% | 30.99% | 29.13% | 28.00% |
D&A For EBITDA | 18,541 | 10,571 | 7,498 | 7,526 | 6,626 | 6,130 |
EBIT | 38,998 | 34,398 | 29,261 | 25,724 | 21,400 | 17,693 |
EBIT Margin | 22.36% | 24.61% | 25.41% | 23.98% | 22.25% | 20.80% |
Effective Tax Rate | 25.38% | 25.56% | 28.49% | 29.58% | 32.59% | 36.60% |
Revenue as Reported | 173,482 | 138,862 | 115,394 | 107,858 | 96,653 | 87,046 |